Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Above averageTG Therapeutics is a fully integrated, commercial stage, biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases.
In the company’s own words · 10-K filed Feb 27, 2026 · SEC EDGAR
Business segments
Q2 2026 · $9.1MThe company’s own SEC segment disclosure.
- License$4.5M50%
- License$4.5M50%
TG Therapeutics, Inc. (TGTX) reported revenue of $240M in Q2 2026 (quarter ended June 30, 2026), up 70% from the same quarter a year earlier. That came with a gross margin of 83% and net income of $7.8M (3.2% of revenue). For the full year FY2025, revenue was $616M (+87% year on year) and net income $447M. Its largest product in 2026-Q2 was License at $4.5M, 50.0% of the disclosed total, just ahead of License at 50.0%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.